
Novo's ziltivekimab flops in CKD trial; Artemis and Hermes face uphill path
Novo Nordisk's Zeus phase 3 trial of ziltivekimab failed to reduce major adverse cardiovascular events in patients with CKD and inflammation, despite IL-6 pathway inhibition; the hazard ratio was 0.99, missing the clinically meaningful 0.85 target and causing the trial to miss its primary endpoint. Artemis and Hermes remain the next tests, though analysts have grown skeptical, given the potential multibillion-dollar CKD opportunity and a peak sales projection around $3 billion previously attached to the program. Readouts for Artemis/Hermes are expected in the first half of next year, leaving the pipeline contingent on those results.




